StockData

CytoMed Therapeutics vs XTL Biopharmaceuticals

GDTC and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GDTC and XTLB compare

CytoMed Therapeutics scores higher on the StockData Score (4 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGDTCXTLB
Size and price
Share price$0.774$1.54
Change, 1 year−59.7%−59.1%
Change, 5 years–−87.1%
Beta (5Y)−0.401.21
Employees53
StockData Score
Total score4 (better)0
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score2 (better)0
Dividend score00
Growth
Revenue growth (TTM)367%–
Profitability
Net margin−1227%–
FCF margin−1336%–
Return on equity−51.3%–
Financial health
Debt / equity0.06–
Interest coverage–−6.3×
Current ratio5.17–
Piotroski F-score1–
Ownership
Held by institutions0.10%0.00%
Held by insiders25.9%0.00%
Insider net buying, 12 months$729K–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.